Direct Impact Investment with Global Reach

BUSINESS VALUE
Infection and disease transmission in clinics and hospitals afflict millions in the developing world. Eniware, LLC is poised to provide portable, power-independent sterilization of medical equipment for existing and expanding healthcare anywhere, at any time. Eniware has secured an exclusive proprietary license to Noxilizer, Inc.’s patented nitrogen dioxide (NO2) gas sterilization technology for Africa, Asia, and the Middle East, as well as a global license to develop portable sterilization solutions for military and disaster relief applications. The Eniware business model is founded on sales of both portable sterilization units and the consumables necessary for sterilization cycles. The business has an experienced management team and has made significant operational progress over the last six months.
COMPETITIVE ADVANTAGE
The Noxilizer nitrogen dioxide sterilization technology has significant competitive advantages over existing sterilization technologies: independence from electricity and other infrastructure, low cost, rapid gas package penetration and aeration, better material compatibility, and reduced residue after sterilization. These advantages translate into significant user benefits, particularly in resource-limited or remote environments.
COMMERCIALIZATION STRATEGY
The company is focused on generating near-term revenue by rapidly developing and commercializing portable sterilization units for all licensed markets while seeking additional support from global health organizations such as the WHO, Doctors Without Borders (MSF), and the Red Cross, as well as working with academic institutions and the US Department of Defense.

Seeking $3,000,000. FInancials and Investor materials available to interested parties.